The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy
Open Access
- 1 February 1997
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 8 (2) , 181-185
- https://doi.org/10.1023/a:1008247830641
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Ondansetron Compared with Granisetron in the Prophylaxis of Cyclophosphamide-lnduced Emesis in Out-Patients: A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group StudyOncology, 1995
- Determining a minimal important change in a disease-specific quality of life questionnaireJournal of Clinical Epidemiology, 1994
- Reducing Chemotherapy-Induced Nausea and Vomiting Current Perspectives and Future PossibilitiesDrug Safety, 1993
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patientsEuropean Journal Of Cancer, 1992
- Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapyThe Lancet, 1991
- Methodology of antiemetic trials: A reviewAnnals of Oncology, 1991